Tirzepatide vs Mounjaro: Same Drug, Different Products

Tirzepatide and Mounjaro: Understanding the Relationship

If you have been researching GLP-1 medications for weight loss, you have probably encountered both "tirzepatide" and "Mounjaro" — sometimes in the same sentence. The relationship between these two terms causes a lot of confusion: Mounjaro® is tirzepatide. But that is not the whole story.

Tirzepatide is the name of the active ingredient — the molecule that does the work. Mounjaro® is the brand name under which Eli Lilly markets tirzepatide specifically for the treatment of type 2 diabetes. There is also Zepbound®, which contains the same molecule but is FDA-approved for chronic weight management. And then there is compounded tirzepatide — a third pathway to the same active ingredient, available at significantly lower cost through licensed telehealth providers like AvataCore.

What Is Tirzepatide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist — a molecule that activates two hormonal pathways involved in appetite regulation, insulin secretion, and fat metabolism simultaneously. This "twincretin" mechanism sets it apart from earlier GLP-1 medications like semaglutide, which target only the GLP-1 pathway.

Clinical trials show tirzepatide produces the greatest average weight loss of any non-surgical medication studied to date. The SURMOUNT-1 trial (published in the New England Journal of Medicine, 2022) showed patients on the 15 mg dose losing an average of 22.5% of body weight over 72 weeks. For a 200-lb person, that translates to roughly 45 lbs of average weight loss. Individual results may vary.

For a deeper look at how tirzepatide compares to semaglutide, see our semaglutide vs tirzepatide guide.

Mounjaro: FDA-Approved for Type 2 Diabetes

Mounjaro® received FDA approval in May 2022 as a treatment for type 2 diabetes in adults. It is manufactured by Eli Lilly and sold in pre-filled auto-inject pens in doses from 2.5 mg to 15 mg. Because it is FDA-approved, Mounjaro has been evaluated by the FDA for safety, efficacy, and manufacturing quality for its approved indication.

Importantly, Mounjaro is not FDA-approved for weight loss. Many providers prescribe it off-label for weight management — particularly before Zepbound became widely available. In clinical practice, Mounjaro and Zepbound contain the same active molecule at the same doses, so the clinical effects are virtually identical when used for weight management.

Mounjaro Pricing

Without insurance, Mounjaro® costs approximately $1,000–$1,300 per month at retail prices. Insurance coverage is more common for Mounjaro than for Zepbound because it carries a diabetes diagnosis code — but still requires prior authorization for most plans, and patients without a type 2 diabetes diagnosis may not qualify.

Zepbound: FDA-Approved for Weight Management

Zepbound® is Eli Lilly's tirzepatide product approved specifically for chronic weight management in adults with obesity, or overweight with a weight-related comorbidity. It received FDA approval in November 2023 and uses the same molecule and dose range as Mounjaro®. The clinical effects are the same; the difference is the approved indication — and consequently, the insurance coverage landscape.

List price for Zepbound® without insurance is approximately $1,050–$1,400 per month. Coverage for weight-loss medications is far less consistent than for diabetes medications, meaning many patients paying for Zepbound are doing so entirely out of pocket. See our full tirzepatide cost guide for a detailed breakdown including HSA and FSA options.

Compounded Tirzepatide: The Accessible Alternative

Compounded tirzepatide is a preparation of tirzepatide made by a state-licensed compounding pharmacy in response to a valid prescription from a licensed provider. It is different from FDA-approved branded products such as Zepbound® and Mounjaro® and has not been evaluated by the FDA for safety, efficacy, or quality. Formulation, inactive ingredients, and clinical effects may differ from the FDA-approved branded versions.

The primary advantage of the compounded route is cost and access. Compounded tirzepatide through telehealth providers like AvataCore typically costs $200–$400 per month, with introductory offers as low as $149 for your first month. For patients without insurance coverage for GLP-1 medications — which describes the majority of Americans seeking weight-loss treatment — the difference is substantial. See AvataCore pricing → for current plans.

Side-by-Side Comparison

Active Ingredient

All three: tirzepatide. The dual GIP/GLP-1 mechanism is the same across Mounjaro®, Zepbound®, and compounded tirzepatide preparations.

FDA Status

Mounjaro: FDA-approved for type 2 diabetes.
Zepbound: FDA-approved for chronic weight management.
Compounded tirzepatide: Not FDA-approved. Prepared by a licensed compounding pharmacy under a valid prescription. Not evaluated by the FDA for safety, efficacy, or quality.

Intended Use

Mounjaro: Type 2 diabetes (weight loss is off-label but clinically common).
Zepbound: Chronic weight management in adults with obesity or overweight with comorbidities.
Compounded: As directed by your prescribing provider; used clinically for weight management.

Cost Without Insurance

Mounjaro: ~$1,000–$1,300/month.
Zepbound: ~$1,050–$1,400/month.
Compounded tirzepatide: typically $200–$400/month; introductory offer as low as $149 first month at AvataCore.

Insurance Coverage

Mounjaro: More commonly covered for type 2 diabetes; prior authorization usually required.
Zepbound: Inconsistently covered; many commercial plans and Medicare exclude weight-loss medications.
Compounded: Generally not covered by insurance; most patients pay cash.

Formulation

Mounjaro / Zepbound: Standardized pre-filled auto-inject pens in doses fixed by Eli Lilly.
Compounded: Customized preparation by a licensed pharmacy; doses can be titrated by your provider based on your response.

Who Should Choose Each Option?

Mounjaro May Be Right for You If…

You have a type 2 diabetes diagnosis and your insurance covers Mounjaro with manageable co-pays. The FDA-approved formulation offers the highest regulatory certainty, and the diabetes indication increases the likelihood of insurance reimbursement compared to weight-loss-only coverage. Your provider may also prescribe it off-label for weight management if clinically appropriate.

Zepbound May Be Right for You If…

You have qualifying insurance coverage for weight-loss medications. It is clinically identical to Mounjaro but FDA-approved for the weight-loss indication. Eli Lilly manufacturer savings programs may reduce out-of-pocket costs for eligible commercially insured patients.

Compounded Tirzepatide May Be Right for You If…

You do not have insurance coverage for GLP-1 medications and are looking for meaningful access at significantly lower cost. Compounded tirzepatide requires working with a licensed provider and a reputable compounding pharmacy. AvataCore's clinical team oversees every prescription, monitors your progress, and adjusts dosing based on your individual response. Compounded medications are not FDA-approved.

The Bottom Line

The active molecule is the same across all three options. The meaningful differences are regulatory status, intended indication, and cost. For patients with solid insurance coverage, the brand-name products offer established regulatory standing. For the majority of Americans paying out of pocket, compounded tirzepatide offers access to the same active ingredient at a fraction of the brand-name price — under appropriate medical supervision.

For more detail, see our compounded tirzepatide guide, our Zepbound vs compounded tirzepatide comparison, and our tirzepatide dosing schedule.